BR9814370A - Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. - Google Patents

Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.

Info

Publication number
BR9814370A
BR9814370A BR9814370-0A BR9814370A BR9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A BR 9814370 A BR9814370 A BR 9814370A
Authority
BR
Brazil
Prior art keywords
recombinant
fusion protein
protein
rhabdovirus
heterologous fusion
Prior art date
Application number
BR9814370-0A
Other languages
English (en)
Inventor
Michel A Whitt
Clinton S Robinson
Original Assignee
Univ Tennessee Research Corp A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Research Corp A filed Critical Univ Tennessee Research Corp A
Publication of BR9814370A publication Critical patent/BR9814370A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"RABDOVìRUS RECOMBINANTE CONTENDO UMA PROTEìNA DE FUSãO HETERóLOGA" A presente invenção refere-se a uma composição que compreende um Rhabdovírus recombinante ou geneticamente projetado que expressa uma Proteína de Fusão, tal como a proteína F da cepa SV5 de Paramyxovírus. Esse Rhabdovírus recombinante pode expressar outras proteínas de ligação que não de Rhabdovírus e/ou uma proteína intensificadora. A invenção também se refere a métodos de formação de Rhabdovírus recombinantes que expressam uma Proteína F. Essas composições recombinantes podem ser utilizadas para fins de pesquisa, bem como para composições de diagnóstico e terapêuticas para o tratamento de doenças.
BR9814370-0A 1997-12-22 1998-12-22 Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga. BR9814370A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6847297P 1997-12-22 1997-12-22
PCT/US1998/026084 WO1999032648A1 (en) 1997-12-22 1998-12-22 Recombinant rhabdovirus containing a heterologous fusion protein

Publications (1)

Publication Number Publication Date
BR9814370A true BR9814370A (pt) 2000-10-10

Family

ID=22082797

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814370-0A BR9814370A (pt) 1997-12-22 1998-12-22 Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.

Country Status (14)

Country Link
US (2) US6497873B1 (pt)
EP (1) EP1040198B1 (pt)
JP (1) JP4544497B2 (pt)
AP (1) AP1968A (pt)
AT (1) ATE451466T1 (pt)
AU (2) AU752004B2 (pt)
BR (1) BR9814370A (pt)
CA (1) CA2316033A1 (pt)
DE (1) DE69841372D1 (pt)
IL (2) IL136905A0 (pt)
MX (1) MXPA00006184A (pt)
NZ (1) NZ505312A (pt)
OA (1) OA11432A (pt)
WO (1) WO1999032648A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517573A (en) * 1999-09-17 2004-02-27 Pro Virus Inc Sequences of the oncolytic virus strain vesicular stromatitis virus (VSV)
AU2001281151A1 (en) * 2000-08-24 2002-03-04 Thomas Jefferson University Rhabdovirus-based vectors to express high levels of functional human antibodies
WO2002072776A2 (en) * 2001-03-09 2002-09-19 The Regents Of The University Of California Cell culture system for synthesis of infectious hepatitis c virus
JP2004537305A (ja) * 2001-07-11 2004-12-16 ユニバーシティー オブ マイアミ 腫瘍細胞の処置のための組換えｖｓｖ
US7820435B2 (en) * 2002-02-06 2010-10-26 Expression Technologies Inc. De novo synthesized plasmid, methods of making and use thereof
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
ES2319424T3 (es) 2003-03-27 2009-05-07 Ottawa Health Research Institute Virus mutantes de la estomatitis vesivular y sus usos.
AU2004265232A1 (en) * 2003-06-05 2005-02-24 Wyeth Holdings Corporation Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
EP1633860A2 (en) 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
CA2663034C (en) * 2006-09-15 2016-05-03 Ottawa Health Research Institute Oncolytic rhabdovirus
WO2009014878A2 (en) * 2007-07-06 2009-01-29 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
EP2398496B1 (en) 2009-02-20 2015-08-05 International AIDS Vaccine Initiative Vesicular stomatitis virus vectors encoding hiv env epitopes
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (en) 2011-10-27 2013-05-01 Christopher L. Parks Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9555067B2 (en) 2012-04-18 2017-01-31 Mayo Foundation For Medical Education And Research Replication-competent vesicular stomatitis viruses
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
WO2018204694A1 (en) * 2017-05-03 2018-11-08 Biomarin Pharmaceutical Inc. Improved lentiviruses for transduction of hematopoietic stem cells.
KR20240073085A (ko) 2017-05-10 2024-05-24 파마 싱크, 엘엘씨 암 치료용 보체 불활성화 내성의 외피 바이러스
EP4100420A1 (en) * 2020-02-06 2022-12-14 Boehringer Ingelheim Vetmedica GmbH Polypeptides useful for detecting anti-rhabdovirus antibodies

Also Published As

Publication number Publication date
AU1905699A (en) 1999-07-12
JP2001526901A (ja) 2001-12-25
US6497873B1 (en) 2002-12-24
IL136905A0 (en) 2001-06-14
JP4544497B2 (ja) 2010-09-15
AU2002300207B2 (en) 2006-07-13
AU752004B2 (en) 2002-09-05
DE69841372D1 (de) 2010-01-21
ATE451466T1 (de) 2009-12-15
AP2000001852A0 (en) 2000-06-30
EP1040198A1 (en) 2000-10-04
AP1968A (en) 2009-04-30
OA11432A (en) 2004-04-26
MXPA00006184A (es) 2003-02-11
WO1999032648A1 (en) 1999-07-01
EP1040198B1 (en) 2009-12-09
NZ505312A (en) 2003-01-31
US20030138457A1 (en) 2003-07-24
CA2316033A1 (en) 1999-07-01
IL136905A (en) 2007-10-31

Similar Documents

Publication Publication Date Title
BR9814370A (pt) Rhabdovirus recombinante contendo uma proteìna de fusão heteróloga.
CL2020000252A1 (es) Muteínas de interleucina 21 y métodos de tratamiento.
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
DE60238472D1 (de) Abschwächung der immunogenizität von fusionsproteinen
ES2174855T3 (es) Metodos diagnosticos y composiciones farmaceuticas que se basan en proteinas notch y acidos nucleicos.
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
DK382786A (da) Overfladeaktivt rekombinant-alveolarprotein
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
DE69840195D1 (de) Verfahren und zusammensetzungen zur behinderung der vervielfältigung von hiv-1
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
AR059371A1 (es) Terapia genica para la enfermedad de niemann-pick tipo a
ES545760A0 (es) Procedimiento para preparar peptidos liberadores de la hormona del crecimiento.
AR013529A1 (es) Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.
BR112022010321A2 (pt) Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
AR024430A1 (es) Proteinas insecticidas y combinaciones sinergicas de las mismas
WO2002085305A3 (en) Compositions and methods for inducing cancer cell death
DK0811068T3 (da) Humane DNase I varianter
AR019851A1 (es) Proteina sustancialmente pura con actividad similar a scarface 3 in vivo o in vitro; analogos de proteina scarface 3; aislados de compuestos de acidosnucleicos que codifican dichas proteinas; vectores que incluyen dichos compuestos de acidos nucleicos; celulas huespedes que poseen dichos vectores yf

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements